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Translational Medicine (TM) in Qatar is part of a concerted effort of the Qatari medical and scientific leadership
supported by a strong political will by Qatari authorities to deliver world-class health care to Qatari residents while
participating in the worldwide quest to bridge the gap between bench-to-bedside-to-community. TM programs
should embrace the Qatar National vision for research to become an international hub of excellence in research
and development, based on intellectual merit, contributing to global knowledge and adhering to international
standards, to innovate by translating new and original ideas into useful applications, to be inclusive at the national
and international level, to build and maintain a competitive and diversified economy and ultimately improve the
health and well-being of the Qatar’s population. Although this writing focuses on Qatar, we hope that the thoughts
expressed here may be of broader use for the development of any TM program particularly in regions where an
established academic community surrounded by a rich research infrastructure and/or a vibrant biotechnology
enterprise is not already present.There are three golden rules for the effective treatment
of any disease. . ..
Unfortunately, we do not know any of themIntroduction
Translational Medicine (TM) in Qatar is part of a con-
certed effort of the Qatari medical and scientific leader-
ship supported by a strong political will by Qatari
authorities to deliver world-class health care to Qatari
residents while participating in the worldwide quest to
bridge the gap between bench-to-bedside-to-community.
Within a commitment from Qatar’s authorities to spend
2.8% of the government’s revenue in research and devel-
opment, TM stands as part of the National Health Strat-
egy 2011–2016 (NHS), to be conducted in accordance
with the priorities established by NHS and coordinated
by the recently formed Qatar Medical Research Council
(QMRC). In addition, TM can and should provide cre-
ative solutions stemming from current basic and clinical
science knowledge beyond those described by NHS. TM* Correspondence: fmarincola@mail.cc.nih.gov; frm2020@qatar-med.cornell.edu
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distribution, and reproduction in any mediumembraces the Qatar National vision to become an inter-
national hub of excellence in research and development,
based on intellectual merit, contributing to global know-
ledge and adhering to international standards, to
innovate by translating new and original ideas into useful
applications, to be inclusive at the national and inter-
national level, to build and maintain a competitive and
diversified economy and ultimately improve the health
and well-being of the Qatar’s population. Although this
writing focuses on Qatar, we hope that the thoughts
expressed here may be of broader use for the develop-
ment of any TM program particularly in regions where
an established academic community surrounded by a
rich research infrastructure and/or a vibrant biotechnol-
ogy enterprise is not already present.
Definition and Interpretation of Translational Medicine
a. A broad definition of TM leaves open and vague
boundaries that allow a comprehensive understanding
of its purposes but make difficult the clarification of
its goals and application.
The Qatar National Research Fund (QNFR) recog-
nizes three categories of research and development:
basic research, applied research and experimentalCentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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“original investigation but, contrary to basic research,
it is directed primarily towards a specific practical
aim or objective”.1 Experimental development is “sys-
tematic work, drawing on existing knowledge which is
directed to producing new materials, products or
devices, to installing new processes, systems and ser-
vices”. Interestingly, in the Zerhouni Group, LCC
(TZG) report consisting of a blue ribbon panel com-
missioned by the QF under the leadership of the
former National Institutes of Health, USA Director
Elias Zerhouni on “Enhancing Qatar’s National Re-
search Enterprise”, a distinction is made between ap-
plied research and translational research: while
applied research is “designed to discover new know-
ledge that can help address the specific needs of
Qatar and the region”, translational research “bridges
the gap between bench-to-bedside-and-back to better
understand disease epidemiology and specific charac-
teristics in Qatar”. An argument could be made that
translational research or, more specifically, transla-
tional medicine sits astride applied research and ex-
perimental development.
We recently prepared an entry on translational medi-
cine for the Encyclopedia Britannica [1] that encom-
passes previous definitions from our group [2-4]. We
defined TM as “research to improve health and longevity
by determining the relevance to human disease of novel
discoveries in the biological sciences. TM is a bidirec-
tional concept, which encompasses bench-to-bedside fac-
tors that seek to increase the efficiency of therapeutic
strategies tested in humans, and bedside-to-bench factors
that provide feedback about the effects of treatment. Assess-
ments are dependent on tools for the characterization of
disease processes and the generation of novel hypotheses
based on direct human observation”. While this defin-
ition, as the ones mentioned in the previous paragraph,
provides a comprehensive overview of the TM concept,
in practical terms, it leaves open and vague boundaries
that cloud the demarcation of targeted efforts and con-
fuse the application of TM, particularly, when resources
for distinct projects need to be prioritized. Therefore, a
more stringent, “working definition of TM” might better
guide TM activities particularly during the development
stage.
b. A stringent definition of TM enlightens goals: what
TM is and what it is not
The core of TM is the integration of novel technical
developments relevant to biomedical discovery for the in
depth understanding of biological processes directly
related to human disease. In other words: how can the
clinical sciences take advantage of the rapidly expandingknowledge and evolving technology to pursue health bene-
fits? Can TM serve as a hub that integrates within one unit
all the components relevant to solve a specific clinically
relevant problem through ad hoc participation of all ex-
pertise from basic or applied research and from experi-
mental development? This working definition implies that
the core of TM is the selection of a precisely defined, clinic-
ally relevant question that should drive the process [5].
Thus, TM should not be confused with broader also clinic-
ally relevant initiatives that have, however, a less defined
end point such as, for instance, the important activities
initiated by research institutes or centers (e.g. the Qatar
Biomedical Research Institute (QBRI), the Cardiovascular
Research Institute, the Drug Discovery Center and the
National Qatar Biobank), which play complementary but
distinct roles. The scope of these initiatives is broader and
overreaching while TM should take advantage of close con-
tact with human material prospectively obtained in clin-
ical settings to answer carefully selected contemporary and
salient clinical questions.
The goals of TM in Qatar
Qatar-specific TM goals should take into account the
relatively early stage of the enterprise and the limited
availability of human and technical resources. Thus,
through a gradual process, a balance should be stricken
between breath of scope and depth of output. Prove of
concept initiatives should be carefully selected according
to the following hierarchy:
c. Focus on the solution of health care problems
prevalent in Qatar and the Middle East and North
Africa (MENA) region to:i. Address in the short-term immediate local and
regional needs to improve the health and quality of
life of the population
ii. Exploit scientific opportunities, while addressing
local and regional needs, to contribute to the
broader goal of understanding disease and
improving treatment strategies of global impact
d. Tackle health care problems of worldwide impact
though relevant to Qatar and the MENA region
delivering cutting edge experimental care at par with
top institutions across the world and to become a
magnet for:
i. Qatar is currently seeking specialized health care
services abroad
ii. The MENA community
iii. The worldwide community through the
development of unique programs in specific areas
of excellence
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We have extensively discussed in the past the obstacles
generally faced by TM [6-8]. Here, we focus on topics
pertinent to Qatar referring to general issues as relevant.
The NHS outlines challenges and potential solutions to
the improvement of health care delivery in Qatar; the
goal is the provision of a “comprehensive world-class
healthcare system including: effective and affordable ser-
vices, coverage of preventive and curative health care
and high quality research directed at improving the ef-
fectiveness and quality of health care”. Clearly, TM in
Qatar should support and at the same time benefit from
NHS initiatives; some best collimate with the purposes
of TM and are highlighted below. As suggested by TZG,
prioritization should follow a stepwise process:
e. Setting biomedical research priorities based on:i. Relevance
ii. Risk-Reward ratio
iii. Return on investmentWhile setting priorities, it will be important to evaluate
the potential of proposed projects to achieve the set goals
within a reasonable time allowing at the same time flexibil-
ity for expansion from the original timeline upon achieve-
ment of encouraging milestones. Flexibility should be
applied also to the reassessment of original plans accord-
ing to promising and unexpected results. Nevertheless,
using the potential scientific impact of a given proposal in-
dependent of outcome as a guiding principle for evaluation
should safeguard from the selection of risky and open-
ended initiatives with minimal likelihood of affecting the
health of Qatar’s population in the first place and more
broadly Qatar’s social and economic development.
A road map to the prioritization of salient health care
problems in Qatar is provided by the NHS, here are out-
lined those mostly relevant to the establishment of a TM
program:
f. Current Health Care needs to be prioritized:i. Research Area Priorities in Qatar are outlined by the
Rand Group Study [9], as summarized in the Qatar
Foundation (QF)/QNFR website where salient





 Women’s and children's health
 Genomic factors on health of individuals and
population Cancer (breast, hematological, colon, and
malignancies)
 Health and environmental pollution
In addition to these, other emerging priorities have
been identified that include:
 Infectious diseases
 Neurosciences (mental health, brain injury and
epilepsy)
 Management of traumaThe TM program will need, at least at the onset, to ad-
just its focus according to the roadmap established by
NHS. Here, we add specific comments illustrating how a
TM program may provide original contributions for the
achievement of these National goals. The chronic dis-
eases outlined by the RAND Group Study are the major
cause of mortality in Qatar accounting for approximately
50% of deaths and the prevalence is even higher among
Qataris. The TM program should develop specialized
experimental treatments for each of them by providing
the clinical research infrastructure as later described in
the strategy section. For instance, the National Cancer
Strategy (NCS) [10] outlines an ambitious and compre-
hensive cancer treatment program spanning education,
awareness, prevention, early detection and advanced ter-
tiary care. Importantly, the NCS includes a research
component “by involving the diverse research community
and the people of Qatar, new insights will emerge that
can enhance the recommendations within the strategy”.
The TM program should support the research aspects of
NCS by providing novel insights in the early diagnostic
and staging of cancer; an example could be the participa-
tion to worldwide initiatives such as the colon cancer
immunoscore project [11] sponsored by the Society of
the Immunotherapy of Cancer [12], which is redefining
cancer staging. The TM program may initiate in Qatar
world class, cutting edge experimental therapeutic strat-
egies, particularly early phase trials such the US National
Cancer Institute Personalized Cancer Care/Drug Devel-
opment Platform [13], testing of pathway inhibitors,
check point and/or microenvironment modulators [14],
immunotherapy [15] and cell therapy [16]. Few targeted
proof of principle early phase clinical trials should be
considered to attract Qataris to seek medical care in
their own Country instead of going abroad for cancer
care, while people from the Gulf region, and even further
afield, will want to come to Qatar for cancer treatment.
Several of these approaches are relatively simple to im-
plement, on an outpatient basis and proven to be effect-
ive, vaccines against the development/recurrence of
cervical [17,18] and lung cancer [19] could be tested.
Similar approaches could be implemented for the study
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and childhood obesity [21]. Partnership with entities like
the Sidra Hospital dedicated to Women and Child health
will be important, particularly in areas like vaccination
against human papilloma virus, or other childhood and
adult vaccination programs for which even at the global
level little is known about individual variability in re-
sponse. Moreover, other interesting questions could be
explored related specifically to the Qatari women such as
the relationship between breast cancer prevalence/sur-
vival and vitamin D deficiency [22,23] in the context of
suboptimal light exposure [24].
ii. It is important to outline some characteristics of the
Qatari residents including Qatari nationals and
expatriates, each with specific sets of health related
issues. A recent census of the Qatar population can
be accessed at [25].
According to the Qatar Statistics Authority, on Sep-
tember 30th 2010, there were 1,624,235 Qatari residents,
approximately 350,000 of whom being Qatari citizens.
The remaining residents were expatriates mainly from
South Asia and from non-oil-rich Arab states. There are
sub-population-specific, health care related problems
that need to be considered separately. Although this
report is not intended to provide a comprehensive over-
view, some examples are deemed necessary. For in-
stance, communicable diseases are more prevalent in
the expatriate population and, consequently, the preva-
lence of cancer in the expatriates is also biased by the
occurrence of pathogen-dependent neoplasia. This vari-
ation may affect the selection of screening and vaccin-
ation programs on one side and their success rate on the
other. Trauma is a significant problem in Qatar, but
while car accidents are responsible for death and disabil-
ity across Qatari residents, work-related injuries are spe-
cific to the expatriate laborers. Women health also bears
regional idiosyncrasies as outlined by the NHS. Perhaps,
the most striking sub-population-specific peculiarity is
consanguinity, which is specific to the Qataris as dis-
cussed later.
iii. TM should support and at the same time benefit
from the “Disease Management Program” for
chronic diseases
TM is a natural partner in the implementation of
long-term disease management programs. Most in
depth studies on chronic diseases such as diabetes, car-
diovascular disease and cancer require long-term follow
up that is best performed in the setting of a disease
management program. TM can participate in a bilateral
exchange bya. Supporting long term treatment of chronic disease
with:
 Novel therapies that can be applied when standard
approaches fail
 Identification and testing of pre-clinical tools for
the rapid screening of new therapeutic strategies
 Supporting patient stratification through the
identification of prognostic, predictive and
surrogate biomarkers
b. Benefit by collecting prospectively human material
that could be studied longitudinally for the
identification of determinants of:
 The natural history of disease
 Responsiveness to standard or experimental
treatment
 Identification of novel prognostic, predictive,
mechanistic and surrogate biomarkers
iv. How can TM be integrated with studies related to
consanguinity –
The current rate of consanguinity among Qataris is 54%,
the most common type occurring among first cousins
(34.8%) making Qatar one of the highest prevalence areas
in the world [26]. It is even likely that the rate of homozy-
gosity is higher than the number of cases recognized to be
directly related because marriage within close communi-
ties has been a long-established custom [27]. Consanguin-
ity among first cousins corresponds to a 5% risk of having
a child with severe or lethal medical conditions. The opti-
mal solution to the problem is obviously prevention
through pre-marital counseling. However, the current real-
ity claims the need and offers the opportunity to study the
genetics of recessive single-gene disorders. This, in turn,
provides the opportunity for the study of gene-specific
dysfunction through the development of a “functional
mapping” program associated with a genetic counseling
clinic; a scientific need of global impact. Moreover, the re-
lationship between consanguinity and the severity of
multi-genic complex diseases of adulthood [27] could be
investigated in Qataris better than in most populations
worldwide. For instance, is the high prevalence of type II
diabetes in Qataris only related to socio-economical fac-
tors, or could endogamy and consanguinity play a role?
Several lines of work have recently pointed at genetic
determinants regulating glucose homeostasis [28] and
affecting the susceptibility to acquire type II diabetes
[29,30]. Genetics studies related to diabetes and obesity
are currently being conducted at WCMC-Q as well as
QBRI; a translational unit integrated with the current
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efforts. The same reasoning could be applied to cancer (i.e.
breast cancer, [31]), cardiovascular disease [32] and other
disorders [27]. Thus, a concerted effort involving all
Qatari stake holders such as the Hamad Medical Cor-
poration (HMC), the Shafallah Medical Genetics Center
(SMGC), QBRI and WCMC-Q, facilitated by the TM
program could tackle not only problems relevant to the
Qatari population but address at the same time unsolved
global genetic questions that have been poorly investi-
gated [27] taking advantage of the uniqueness of the
Qatari population: in this case these efforts could test
the hypothesis of whether increasing genome wide het-
erozygosity leads to reduction in burden of common
genetic diseases.
v. How can TM support efforts to build local capacity
The QF, with the establishment of Education City, has
taken a leadership role among Countries in the Gulf Re-
gion and the MENA region in modeling the integration
of higher education with research and development [4].
The TM program should actively participate in the educa-
tion and training of clinical investigators at different levels
bridging educational activities in the basic sciences pro-
vided by WCMC-Q with training opportunities at HMC,
Women’s Hospital, Sidra, SMGC, other local hospitals and
centers, and eventually the TM program (for training in
TM research). Consequently the TM program should
participate in building Qatar-based residency programs
providing training in clinical and translational investiga-
tion. The latter will serve not only the need to build local
capacity but also serve a global need. In particular, the high
cost and delay of revenue due to prolonged medical
training has limited the number of available clinical inves-
tigators worldwide [33,34]. TM in Qatar, supported by
designated funds from the QF/QNFR should establish and
manage competitive fellowships to attract young investiga-
tors worldwide and contribute to the solution of this glo-
bal problem. This could be done by establishing an elite
clinical investigation fellowship program with competitive
salaries, research support and infrastructure similar to the
clinical research fellowship programs established success-
fully at the National Institutes of Health (NIH) that rigor-
ously complement clinical with basic research training. In
addition, special incentives and programs should be estab-
lished to facilitate a natural continuation from the TM fel-
lowship into a clinical research faculty position in Qatari
institutions including transitional appointments (senior
fellowships) for those not quite ready to become inde-
pendent investigators.
vi. How can TM be integrated with the healthcare data
project and the E-health programA current major challenge for the success of biomed-
ical investigation is the integration of biological data with
high quality and comprehensive clinical and epidemio-
logical information. Thus, TM should support any at-
tempt to integrate information and at the same time
benefit from such efforts. The TM program should also
provide open access to patient-specific information (re-
spective of privacy rules) that may benefit the general
purposes of the health care data project and in general
medical practice in associated institutions.
vii. How TM can be integrated with the growing Public
Health initiatives and an increased emphasis of
primary care centers
TM can contribute to Public Health and Preventive
Health care by identifying novel biological surrogate
markers to monitor the effectiveness of preventive efforts
particularly at the preclinical stage, which are currently
not available for most chronic diseases. At the same
time, a close relationship with primary care givers could
start a bidirectional process for exchange of research ma-
terial addressing prevalent conditions in the Qatar’s resi-
dents, while providing clinically useful information based
on novel advances in biomedicine.
viii. Engaging basic scientists
The Federation of American Societies for Experimental
Biology (FASEB) in association with the Howard Hughes
Foundation, the Burroughs Wellcome Fund, the US De-
partment of Veterans Affairs, the Doris Duke Charitable
Foundation, and Merck Sharp & Dome Corp. organized
a symposium on “Engaging basic scientist in transla-
tional research: identifying opportunities, overcoming
obstacles” that resulted in a document providing guide-
lines and reporting on a survey inclusive or 2,000 investi-
gators [35]. It should be recognized that basic science is
the foundation of the biomedical research enterprise
since it provides a logical interpretation of observations
that facilitates solutions of medical problems through a
systematic rather than empirical process. Yet, “in spite of
major advances in fundamental biology, there is wide-
spread concern about the slow pace at which these dis-
coveries are translated into sage and effective clinical
interventions. . .Numerous initiatives to speed translation
are under way, many of which have been aimed at pro-
viding clinical scientists with the knowledge and tools
needs to translate research discoveries into improved
patients care. Less attention, however, has been given to
the contributions that basic scientists make to the process
of translational research” [35]. It was recognized that sev-
eral obstacles face the basic scientist willing to participate
in TM initiatives spanning the scientific, institutional,
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that while TM best fits a multi- and interdisciplinary
modus operandi, the research environment encourages
specialization and rewards individual achievement and
hypothesis-driven, investigator-initiated research. We
refer to the FASEB report for a comprehensive overview
of this issue; however, it is pertinent to emphasize in this
document the importance of engaging the basic science
community in Qatar as anywhere else. This can be
achieved by providing special rewards to supplement the
classic academic process targeting those scientists want-
ing to significantly participate in TM initiatives, parallel-
ing the model described later for the rewarding of
clinical scientists directly involved with TM initiatives.
In fact, nearly three-quarters of respondents to the
FASEB survey indicated that their primary motivation to
embark in TM efforts was to have in impact on human
health [35] but their involvement was hampered by the
rewarding system. Participation of basic scientists to
TM and in general clinical research also benefits institu-
tions; successful development of new drugs, devices and
procedures attract patients who want to benefit from
cutting edge research, and attract funding from other
public and private sources at the international level.
There is also the practical reality that most often basic
scientists work in locations afar from clinical scientists;
this poses a physical barrier to vibrant interactions that
bears bigger weight than generally recognized. For this
reason it would be reasonable to create dedicated space
on a per needed basis for basic scientists actively
involved in TM research to encourage their part time
presence within the TM community. In addition, special
lecture series could be organized where related basic and
clinical science topics should be sequentially presented
and participation of all involved in the TM initiative
should be encouraged or even enforced. Finally, as pio-
neered by the Moores Cancer Center, San Diego, CA,
USA (as an example) space may be dedicated around
TM facilities to host industrial activities and minimize
geographic distance as a biotechnology incubator [36]. A
similar model could be expanded to host few highly rele-
vant basic science laboratories.
ix. Fostering public/private partnership
The development of a biotechnology corridor around
the QF is encouraged and planned particularly through
the creation of the Qatar Science & Technology Park
(QSTP). QSTP has been quite successful in facilitating
the engagement of the private sector with universities,
as a base for multinational and national companies to
establish programs in Qatar. However, currently, these
initiatives are predominantly in the development phase
and Qatar does not enjoy the nurturing environment ofa rich biotechnology community surrounding some
major academic centers elsewhere such as Stanford Uni-
versity, Harvard University, and University of California
in San Diego, to use a few examples. This is, of course,
not unique to Qatar as most academic centers both in
developed and developing Countries are not necessarily
adjoined by a large private enterprise endowed with
affluent venture capital. Moreover, large pharmaceutical
companies are distant geographically and not used to
interact with Qatar and the MENA region. In particular,
the relatively small population of Qatar (including
Qatari and expatriates) may not lend to big Pharma
interest in supporting large-scale clinical trials. How can
these hurdles be overcome? The following may repre-
sent potential solutions:
 Provide incentive to industry limiting overhead
financial burdens (indirect cost) that hamper public/
private interactions in other Countries
 Decrease regulatory hurdles by surgically dissecting
unnecessary from necessary regulations regarding
issues such as protection of patients safety and
privacy, conflict of interest regulations, intellectual
property issues; this could be done by taking a
leadership role rather than following; a world class
bioethics research institute aimed at streamlining
rather than enhancing regulation and working
together with the TM program should be considered
 Encourage recruitment in high profile clinical trials
from the surrounding MENA region offering free or
reduced cost medical care (for experimental trials)
and potentially travel support following the NIH
model
 Focus on early phase clinical trials as proof of
concept rather than late phase trials that may
require larger patient populations
 Complement industry-sponsored trials with high
quality correlative studies of high academic impact
(rewarding the TM program) and valuable clinical
impact for outcome interpretation (useful to
sponsoring partner) providing matching funds and
sharing potential intellectual property
 Provide areas of expertise in costly cutting edge
technologies whose services could be offered in a
collaborative form to small biotechnology enterprises
that would not otherwise have access
 Provide financial and administrative infrastructure
following the venture capital model pioneered by the
Accelerator [37]. This model provides starting funds,
management, laboratory space and financial
expertise to competitive start-ups, therefore,
facilitating the transition from the academic to the
commercial world with the purpose of turning
promising technologies into powerful business.
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collaborative approach rather than a financial gain
expectation. Often, the contribution of industry to
the academic enterprise is disproportionally looked
upon as potential funder rather than intellectual
exchange. In reality, industry partners can
contribute significantly to the research and
development process and should be engaged from
the onset.g. Logistical challenges specific to Qatari. Small health research workforce
(human resources)
ii. Institutional immaturityThere is a clear limitation in the current and the
projected work force in Qatar for the next decade.
The problem is compounded by the expected rapid
growth in number of Qatari residents, particularly
expatriates that will result in increased health care
demand. Thus, as per the TZG report, the capacity of
Qatar to “conduct projects on a broad front is cur-
tailed by its current small health research workforce
and by institutional immaturity with. . . loose connec-
tions between research and the health care delivery
system”. In particular, it appears that, in the enthusi-
asm of building a world-class research infrastructure,
several institutions with overlapping goals are sprout-
ing. This is not necessarily a negative occurrence
particularly if their activities can be effectively coordi-
nated by the QMRC to avoid turf battles and overlap-
ping projects but rather encourage complementarity
of goals and resources. The NHS is taking several
steps to enhance workforce planning, increase re-
cruitment and retention and improve professional
education in loco. At the same time, although facil-
ities and infrastructure is rapidly being built there are
still areas in significant need for technical support.
As well articulated by the TZG report, “too often,
Countries that pursue a knowledge economy find
themselves facing a disconnect between their aspir-
ation and the reality of their existing human capacity
and physical resources. . .. An unappreciated mis-
match between what can be done, what should be
done, and by who is the most common cause of failure. . .It
will be important to strike a balance between breath of sci-
entific representation and depth in areas deemed to be of
national importance”. We believe that it is also import-
ant to establish key collaborations and partnerships
with institutions abroad to facilitate transfer of know-
ledge and technology following effectiveness princi-
ples well described by Thomas Friedman in “the
world is flat” [38].Proposed strategy
Specificity and linearity of goals
The primary principle of the TM strategy will be to avoid
overly ambitious and unfocused efforts as well discussed
by Moore et al. [5] in regard to the planning of pilot
studies. Goals and strategies should be clear and simple
avoiding the addition of unnecessary complexity to
already complex biological and clinical problems and,
most importantly, sheltering lack of focus with prepos-
terous intricacy (“if we make it complicated enough no-
body will have the courage to challenge it!”). Individual
projects should be defined, designed and pursued follow-
ing the rigor applied to hypothesis-driven academic
standards.
iii. Question-driven vs technology-driven strategy
This can be achieved by a concerted effort to identify
the primary clinical needs of local and global impact to
be tackled by the Qatar scientific and clinical commu-
nity. In addition, projected clinical and scientific impact
should be enforced as a guiding principle in project
prioritization to encourage TM researchers to focus on
scientific projects likely to link their research activities
with substantial health improvements through the devel-
opment of novel therapeutics or the creation of clinically
useful commercial products
Prioritization
All initiatives should be assessed for impact and ease of
execution as for the NHS recommendations; in
particular:
iv. To assess the impact:1. Importance of the issue being addressed by the
initiative
2. The expected initiative’s time to impact lag
3. The urgency of the issue addressed
4. Follow a sequential logic of projects (added,
not in NHS)v. To assess the ease of execution:1. The budgetary range
2. The level of skill needed
3. The initiative’s complexityAn example of integration between initial TM projects
and the NHS prioritization strategy is one of the “seven
quick wins: update vaccination programs for adults”.
Target diseases are influenza, pneumococcal infection,
tetanus, diphtheria and pertussis, human papilloma
virus, and herpes zoster. Several of them also pertain to
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efforts are standard in their delivery, patient-specific
outcome of vaccination is highly variable according to
genetic makeup of patients and environmental exposure
even among healthy individuals. For instance, at the
trans-NIH Center for Human Immunology, one of us
(FMM) was recently involved in a study following the
response of 200 healthy volunteers belonging to a rela-
tively homogenous population to seasonal and H1N1
influenza vaccination with an integrated genomics,
functional genomics, deep phenotyping and outcome
approach. This study highlighted huge variations in bio-
logical responses in healthy individuals that could be
partly attributed to previous vaccine exposure and
partly to genetic and biological characteristics (manu-
script in preparation) Thus, a major opportunity arises
to study the effect of vaccination among different popu-
lation (Qatar ethnic diversity? due to a relatively
homogenous core population: Qataris compared with
the heterogeneity of expatriates), while supporting a
prioritized NHS goal.Short term focus – Hypothesis generating/testing clinical
studies
At the onset, the TM program should focus on goals
achievable in the short term following a bedside-to-
bench strategy (Figure 1). The TM program could initi-
ate correlative studies associated with standard of care
treatment or off-the-shelf experimental therapeutic inter-
ventions to identify:
vi. Clinically relevant biomarkers suitable for
commercial application
vii. Knowledge-generating studies to discover novel
concepts elucidating disease patho-physiology that
could foster subsequent investigations at basic,
applied or developmental scientific level
This strategy combines the introduction in Qatar of
emerging therapeutic concepts with provision of mater-
ial for valuable scientific investigation. Critical to the
success of this initial steps will be the creation of a Na-
tional Clinical Trial Registry and develop mechanisms to
facilitate awareness of clinical and research activities
with the Qatari community, the MENA region and of
global reachLong term focus – Investigator-initiated clinical studies
Bench-to-bedside research is a long and costly process.
Only a tiny minority of potential therapeutic candi-
dates reach licensing for commercialization and clinical
application after about a decade of testing and a cost in
the range of billions [7,39]. Moreover, among licensedproducts, only a fraction is profitable. Therefore, it
would not be wise to inaugurate the TM enterprise
with product development as a primary, short-term
goal. On the other hand, the TM program should be
sensitive to and watchful for cutting edge, innovative
ideas emerging from any of the Qatari academic insti-
tutions to support their testing and development in the
clinical settings. TM investigators could help their
basic science colleagues, starting from the envisioned
final product and working backwards, to define the
production pipeline of research steps required to sup-
port such product in the clinics. In addition, TM inves-
tigators should help the “go-no go” decision making
process in late phase pre-clinical assessment before the
cost in human resources and financial involvement
escalates at the transition from laboratory investigation
to clinical settings (Figure 2).Driving philosophy
As for many things in life, there are many ways to suc-
cess or failure; most depend upon an optimized balance
between a broad vision at the conception and sufficient
attention to details during the implementation. We be-
lieve that important components to a successful TM ini-
tiative are: integrity, clarity, and transparency of goals
and flexibility in execution. In our opinion, enterprises
often fail because of lack of effective communication be-
tween the leadership, particularly of large institutions,
and their constituency. Therefore, here we propose
guidelines for the establishment of the TM program that
do not span general concepts related to TM, as plenty
has been written by us [1-3,6,8,40,41] and others [4,42-
65]. Here, we rather focus on principles that are specific
to the successful establishment of a TM program. We
suggest that the following principles should serve as the
foundation of a TM program in Qatar and that some
may apply elsewhere.Open and transparent decision making with a bottom up
infrastructure
It is important for the leadership to maintain direct,
continuous and effective communication with subor-
dinates at all levels to optimize the balance between
general goals and their implementation. The reporting
relationships should not be excessively rigid sheltering
and isolating the top from the bottom of the hier-
archical structure. No matter how busy a leader might
be, she/he should make a priority to communicate
directly with and know his/her own work force. It
does not take much to sample opinions directly: a
good example is the “Undercover Boss” TV series by
Stephen Lambert.
Figure 1 The short-term bedside-to-bench TM model.
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The secret to success in TM is teamwork because the re-
search endeavor requires different sets of skills directed
toward a unified clinical question. However, most clinical
research centers associated with academic institutionsFigure 2 The integrated long-term bidirectional bench-to-bedside-toare currently following a “professional bureaucracy”
model in which departments are segregated according to
area of expertise, therefore, isolating specialties from
each other. We suggest that TM should apply the “ad
hocracy” model described by Mintzberg [66], whichbench TM model.
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necessary to the accomplishment of a given goal are
included. For instance, this model is used for military
special operations where effectiveness in achieving a goal
is paramount. In the context of TM, we propose that the
TM program should be constituted of separate units
built around a clinical scientist, who functions both as
principal investigator for TM unit-initiated projects and/
or co-investigator facilitating projects initiated by other
TM units or by other institutes but supported by and
performed within his/her own unit. Dedicated scientific
and clinical staff and resources should be recruited/
assigned according to goal-specific needs and their
utilization should be flexible. Staff and resources should
be detailed to a TM unit on a permanent or temporary
basis and according to a full or part time schedule
according to need that can be periodically re-assessed.
However, assignments should be person-specific for the
duration of a project while rotations should be mini-
mized. For instance, if a project does not require full
time employment of a specialist (i.e. radiologist, patholo-
gist, surgeon etc.) a part time appointment would be suf-
ficient. However, the specialist should be selected
according to specific interest and knowledge related to
the project and should participate to all the intellectual
activities and not only those pertaining to his/her own
specialty. In other word, each co-investigator at any level
should be an active component of all aspect of a given
TM project. As a corollary, since it would be difficult to
structure a unit around several goals, it is recommended
that project selection should be carefully-evaluated
according to impact of the question addressed, relevance
independent of outcome and rigor of execution.
Team work, clinical relevance rewarding model
The current system of career advancement in science
rewards primarily the individual; similarly publications
list authors according to a rigid hierarchical structure
assuming individual leadership roles and taking little
account of team play. This creates a conflict between
reward structure and expected results when multi-
disciplinary projects are pursued, which are the essence
of TM [6]. It is becoming apparent that large, coopera-
tive and multi-disciplinary groups most often obtain sig-
nificant contributions to the understanding of disease;
the increasing number of publications in high impact
journals demonstrates this with dozens of authors. Thus,
the academic governance to which the TM program is
reporting should implement a TM-specific reward struc-
ture. Professional recognition in the form of financial
support and promotions should be granted according to
impact of work rather hierarchical attribution in given
projects or papers. It should be left to the principal
investigators to evaluate which member of his/her teammost effectively contributes to the TM unit goal(s). This
may be challenging, because it introduces subjective
judgment over the commonly applied objective para-
meters. Contrary to the co-investigators within each unit,
each unit’s principal investigator should be judged
according to the output of the unit independent of his/
her hierarchical position in individual papers/projects. It
is hoped that by holding each principal investigator re-
sponsible for his/her unit productivity rather than his/
her own specific contribution, acknowledgement of con-
tributions will be attributed proportionally to each indi-
vidual’s participation rather than seniority and it will be
in the principal investigator interest to provide accurate
assessment of each member value to retain the most
productive. In addition, projects should be evaluated not
only according to scientific quality but according clinical
relevance. Much has been discussed about parameters to
achieve an objective evaluation of the clinical relevance
of investigation [2,6,8,40,41,67]. However, no specific so-
lution is currently available. We propose that clinical im-
pact could be judged by the type of journals in which
manuscripts are published (more geared toward clinical/
translational investigations), the resulting effects in modi-
fying clinical practice, and the output of potentially useful
products as for instance suggested by granting of patents.
In general, increased sensitivity to the clinical impact of
ongoing investigations should be expected by scientific
advisory councils judging TM activities: “Tenure, promo-
tion, and appointment committees should be challenged to
evaluate the importance and impact of the individual con-
tribution that a single faculty member makes in the context
of a multi-investigator TM project” [35].
Required infrastructure
Substantiating the acquisition of costly equipment
TM does is not: A crystal building with a genomics facil-
ity. The rapid evolution of technology incessantly pro-
duces costly machines, requiring extensive training for
their utilization, having a short life span before being
outdated and requiring costly operational and mainten-
ance support. Thus, their purchase is justifiable and cost
effective only when the instrument can be utilized at full
capacity and soon after acquisition. This is not always
the case as several institutions fall to the temptation of
obtaining “state of the art” equipment to show case with-
out a clear vision of its utilization resulting often in
instruments decanting in alleys, often unpacked. On the
other hand TM cannot be insensitive to innovation.
Thus, we suggest a mixed model to keep abreast with
evolving technology: emerging technologies can be grad-
ually tested in pilot projects through outsourcing even if
the cost per sample is higher than projected given a full
running in house system. This approach evaluates the
usefulness and potential of a given technology with
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the claimed validity. However, purchase of high technol-
ogy costly equipment should be ultimately considered
and encouraged when the novel technology is sound,
long lasting and likely to be operated at close to capacity;
this allows a cheaper overall operational cost per sample
while enhancing the professional qualification of labora-
tory personnel.
The centralized (core facility) resources question
An obvious solution to underutilization is the optimization
of capital investment into centralized/core units. How-
ever, frequently such units are underutilized [68] fail to
provide the expected results and often are neglected by
the potential beneficiaries due to close door policies,
lack of transparency in priority selection, delays in ser-
vice and obscurity in data interpretation. We believe
that the core facility model in itself is not functional if
not carefully crafted according to the needs and struc-
ture of an institution. Each unit, including centralized
ones should be accountable according to academic stan-
dards, without privileged financial support rationalized
as “service”. Centralized facilities should not be built as
service providers but with associated research and devel-
opment capabilities and be lead by a principal investiga-
tor responsible for their academic output using the same
standards applied to other TM units. Financial support
should be dependent upon substantiated academic out-
put evaluated by the quality and relevance of publica-
tions for which the unit was responsible either primarily
or in collaboration with others. In summary, a functional
centralized facility should be assessed and rewarded
according to evidence of collaborative work rather than
been operated in a pay per fee service. Moreover, a func-
tional centralized unit should be open providing access
and teaching to TM investigators willing to learn sample
processing, testing, and data analysis and interpretation
and be accountable according to academic standards.
The special case of Bioinformatics and Computational
Power
In the foreseeable future, while analytical platforms for
genomics, proteomics, metabolomics etc. will continue to
evolve, their output, standardized into computational units
will converge into the pot of data analysis and integration;
therefore, the true bottle neck of biomedical research will
consist in limitations of transforming information into
knowledge unless efforts will focus on keeping up with
expansion of computational power and investment in pro-
gramming tailored to scientific needs.
As the yield of high throughput technology logarith-
mically expands, corresponding needs arise in storage
capacity, data transfer, organization and analysis to
avoid the ever-growing bioinformatics bottleneck [62].Moreover, software programs for interpretation of data
have not caught up with the output of the novel tech-
nologies particularly when non-standard analytical
approaches are required and when integration of infor-
mation from different platform is involved. Interest-
ingly, while several new technologies find rapidly a
home in companies willing to provide as a service their
implementation and, therefore, projects can often out-
sourced at a reasonable cost, it is unthinkable to relin-
quish data handling and interpretation to outside
sources. This model has failed consistently since only
the investigators in close contact with the analysts can
lead the logical steps with the appropriate focus, specifi-
city and accuracy. Thus, a TM unit should include or be
closely associated with a TM bioinformatics support
unit that includes:
 Information technology support
 Programming capability
 Mathematical modeling
 Computational biology/statistics expertise
The TM bioinformatics unit should be primarily re-
sponsible for the development of the infrastructure ne-
cessary for handling and processing large data sets,
guiding scientists and their staff (research fellows, biolo-
gists) in study design with regard to bio-statistical
power, analysis performance and presentation. However,
we suggest that the TM bioinformatics unit should not
run standard data analysis but rather guide scientists
and their staff in performing their own analyses while
the bioinformaticians/statisticians should devote their
time in creation of new programs for high level, non
standard solution to ever growing computational needs.
We argue that, in the context of standard bio-statistical
analyses, the computational biologists’ and statisticians’
time is better used in mentoring research fellows rather
than performing analyses. This strategy will 1) protect
the biostatistician time that can be dedicated to more
creative activities; 2) provide a valuable teaching experi-
ence for scientists and fellows in an emerging scientific
arena; 3) assure that the analytical process follows a
logic process direct through the contribution of the sci-
entist(s) who initiated the study. Finally, the develop-
ment of novel analytical strategies should be the primary
academic goal of the TM bioinformatics unit and should
be rewarded with primary authorship in manuscripts
and/or copyright privileges.
Establish targeted sponsorship from QF/QNRF or other
sources
TM should receive dedicated and stable financial sup-
port from the sponsoring organization (supposedly the
QF/QNFR) for operative costs and equipment. Support
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agreed upon by the supporting parties and the TM lead-
ership. Moreover, financial support should be dependent
and adjusted according to the successful achievement of
clearly established short and long-term targets and mile-
stones. Some European institutions are implementing
a formulaic target-dependent sponsorization system
whereby operational costs are supplemented based on
metrics such as individual publications and their calcu-
lated impact, development of patents and licenses, es-
tablishment of biotechnology enterprises, alternative
support metrics (such as industry support), provision of
matching funds associated with grants or donations
from a third party, etc. Finally, TM investigators should
be able to compete not only in general granting pro-
cesses but also funding mechanisms through an inde-
pendent sub research mechanism dedicated to TM.
Currently, the QNFR defines specific sub research areas
related to health among which Clinical Medicine and
Basic Medicine take the lion’s part. We suggest that a
sub research domain should be created dedicated to
Translational and Applied research with clear demarca-
tion of the goals and purposes of the discipline to
encourage applications for high quality local and inter-
national projects.
Establish a Chief Scientific Officer (CSO) position (distinct
from the Scientific Director)
Key to the success of the TM program is the hiring of a
CSO who will work closely with the Clinical and/or the
Scientific Director(s) and be responsible for managing
the research and technological operations. In particular,
the CSO will be responsible for supervising and coordin-
ating the development of new processes, technologies or
products particularly when they require significant cap-
ital investment and/or interactions among distinct TM
units or other institutions. Institutional leadership is
often focused on the “big picture” building harmony
between the vision of a given institution, the local rele-
vance, its worldwide impact, and the surrounding intel-
lectual and political reality. While these skills are
fundamental for the survival of the institution, they
rarely come in association with detailed technical know-
ledge of the processes required to implement the vision.
This particularly applies to biotechnology and, conse-
quently TM, as methods and tools evolve rapidly and
understanding of their potential value requires contin-
ued hands on evaluation. Thus, too often the implemen-
tation of the vision is scattered without coordination
among lower ranking investigators following a principle
reminiscent of the “trickle-down economy”: the leader
provides the financial support and the scientists, as a
community, will produce something that will approxi-
mate the envisioned product. This strategy, however,dos not apply to TM initiatives, which are often com-
plex, thirsty for ever developing and costly technologies
and multi-disciplinary in character. Thus, a manager
capable of co-coordinating efforts from the bedside-
to-the-bench and vice versa, with in depth expertise
and hands on knowledge of all relevant components
of the process from tissue procurement, to handling,
processing, testing and analysis is necessary to avoid
misuse of resources. Take this example (just one of
many): company X sells a new technology; instrument
cost $ 1,000,000; Dr. Y wants the TM program to buy it
as part of the general operative costs (rather than his/
her own budget) with the rationale that the new tech-
nology will eventually benefit other investigators, while
his/her own laboratory will not utilize the instrument at
full capacity. How will the decision making process be
performed? While the Scientific Director may very well
consider the relevance and impact of the proposed pur-
chase in the context of the institutional vision, who could
knowledgably dissect: what standard operative procedures
for sample collection, storage and preparation suitable for
the new technology will be required; how do they relate to
current collection procedures and available resources,
what are the projected operational and maintenance costs
associated with the instrument, what is the projected pro-
portional utilization related to the capacity and life-span of
the technology, what alternative technologies should be
considered, what is the proportional value of outsourcing
rather than purchasing, what level of training of personnel
will be necessary for the technology to be implemented ef-
ficiently, what kind of support for maintenance will be
available from the company when the instrument is pur-
chased, how will the output be handled, what data storage
and processing tools will be required? It could be argued
that the investigator or the director of a centralized unit
relevant to the purchase could deal with such questions;
in reality, however, an unbiased individual within the
leadership, who can link directly scientific requests with
the overall goals of the institution, can only make this
decision-making process objectively. In summary, the
CSO will flank the Clinical and/or the Scientific Dir-
ector (s) of the TM program by providing internal ex-
pertise to fulfill with “hands on knowledge” the mission
by bridging distinct disciplines coordinate development
and efficiently execute the projected goals.
Proposed time line and prospective metrics to measure
success
It is time for TM efforts to yield results; a large number
of TM institutes have been and are being created world-
wide in the last decade. Most have failed and will fail in
yielding the valued end product: a change in the stand-
ard of care. It is our personal opinion that the failures
are largely due to insufficient attention to details, lack of
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targets in the short and in the long-term. Thus, we be-
lieve that for the successful development of TM in Qatar
(and elsewhere) these guidelines should be prospectively
defined and followed to judge success (here general targets
are listed while details for the evaluation are discussed in
the subsequent section, milestones can only be negotiated
later in the process of establishing the TM program):
a. Clear improvement in health care at the regional and
global level
b. Academic success measured according to scientific
contributions in the clinical research arena
c. Economic impact
d. Development of a critical mass of scientific/
biotechnology enterprise around the TM program
including a biotechnology corridor (incubator)
attractive to world lass investigators
To implement a balanced investment portfolio, the
metrics to success should be adjusted according to 2
timelines:
 Short-term goals
TM initiatives should at the onset focus on short term,
realistically attainable results. We suggest that focused
clinical questions answerable through analysis of already
available or easily obtainable clinical material should
drive the selection of the first generation projects; this
bedside-to-bench approach could focus on the identifica-
tion of useful biomarkers for patient stratification, to
support the Public Health initiatives and for provision of
a road map for future investigations. They should at the
same time generate information and knowledge of sig-
nificant academic impact.
 Long-term goals
Second/advanced generation studies should focus on
impact and not only on feasibility: these studies could fol-
low a bidirectional approach (bedside-do-bench or bench-
to bedside and include 1) the design of complex prospect-
ive clinical trials based on experimental and/or standard
therapies as single agents or in combination with the
purpose of understanding mechanisms of action, identifi-
cation of relevant biomarkers and definition of better thera-
peutic strategies [69-71] or; 2) investigator-initiated clinical
studies to test novel therapeutic or diagnostic concepts.
Evaluation process
Performance Metrics should be prospective
Targets and milestones should be clearly defined from
the beginning and in line with the vision established inaccordance with the NHS, QF and all other involved sta-
keholders. Regular though not overburdening reporting
should be implemented on an annual basis while a peri-
odic internationally based peer review process should be
established. We recommend a “retrospective focus” in the
review process looking at past achievement with minimal
bearing on future initiatives. We believe that intellectual
freedom and ability to “think out of the box” is a require-
ment for a creative approach to TM and the TM scien-
tists should be allowed complete intellectual freedom in
study design being judged only on the impact and rele-
vance of their end product. However, as defined in the
subsequent section, the peer review process could sug-
gest new and unexplored concepts that could integrate
Qatari efforts with worldwide interests.
Specific performance metrics and programs evaluation
viii. Operational objectives and milestones1. Establishment of Faculty Awards to develop
research laboratories in Qatar relevant to TM
2. Recruitment of Clinical/Translational Investigators
3. Implementation and coordination of Bioinformatics
activities
4. Implementation of proof of principle pilot projects
5. Implementation of summer fellowships related to
TM
6. Organization of international conferences
7. Establishment and coordination of core facilities
8. Establishment of administrative support
9. Definition and implementation of core research
projects
ix. Scientific achievements should be judged according
to the definition of clear indicators that are specific,
measurable, achievable, relevant and timely:
1. Publication record in peer-reviewed journals
2. Citations indices such as for instance the H Index
3. Research collaborations at national and
international level
4. Research Awards
x. Program evaluation should include:
1. Annual reporting to the sponsoring institutions
describing the scientific and administrative
operations of the program as well as planned
activities for the following year(s). In addition, a
budget of review and approval for each program
should be presented
2. Periodic (biannual) evaluation by an international
Scientific Advisory Board comprising
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should:
a. Be aimed not only at evaluating the current
results but allowed to provide novel ideas and
suggestions relevant to global health
b. Provide an opportunity to showcase the best
achievements of TM in Qatar and “spread the
word” by informing leaders in the fieldSummary and conclusions
The need to conduct biomedical research with relevance
to and impact on human suffering is summarized by the
TM concept; however, success will depend ultimately in
the effective implementation into a functional reality.
The development of a coordinated TM program, under-
standing the theoretical and practical hurdles facing
such implementation and embracing possible solution
with the necessary rigor and attention to details will ul-
timately determine the achievement of quality results.
Here we propose basic ideas that may help in the
conceptualization of TM programs starting from its
broad scope to the focused implementation of individual
goals. Although the focus is on Qatar, we hope that this
exercise will be of use for the implementation of other
programs elsewhere in the world particularly in areas
where a rich surrounding infrastructure supported by an
established academic community and/or a vibrant bio-
technology enterprise is not already present.
Endnotes
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quote in italic passages from two documents: the Na-
tional Health Strategy 2011–2016 (NHS) or the Zerhouni
Group LCC (TZN) study on “Enhancing Qatar’s National
Research Enterprise”. For more details please refer to the
corresponding authors.
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